Letrozol Aristo

Letrozole, the active ingredient in Letrozol Aristo, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal estrogen receptor‑positive breast cancer.

GNH USA supplies Letrozol Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is used in the management of hormone‑dependent breast cancer in postmenopausal women.

- Postmenopausal estrogen receptor‑positive breast cancer (adjuvant): reduces recurrence risk after surgery. - Postmenopausal estrogen receptor‑positive breast cancer (neoadjuvant): shrinks tumor before surgery. - Metastatic estrogen receptor‑positive breast cancer in postmenopausal women: slows disease progression.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness not relieved by rest. - Nausea: upset stomach, sometimes with vomiting. - Headache: mild to moderate pain in the head. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Severe liver injury: elevated enzymes, jaundice, hepatic failure. - Osteoporotic fractures: increased risk of bone breaks due to reduced bone density. - Pulmonary embolism: blockage of lung arteries, presenting with sudden breathlessness. - Myocardial infarction: heart attack, chest pain, and related symptoms. - Anaphylaxis: severe allergic reaction with rash, swelling, and airway compromise. - Elevated cholesterol leading to cardiovascular events: significant rise in LDL cholesterol.

When prescribing letrozole, clinicians should observe several precautionary measures to minimize risk.

- Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Liver function monitoring: perform periodic liver enzyme tests. - Lipid profile monitoring: check cholesterol levels regularly. - Avoid use in premenopausal women: efficacy is limited and may cause ovarian stimulation. - Concomitant estrogen therapy: discontinue hormonal replacement that may counteract drug effect. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma concentrations. - Estrogen‑containing hormone therapy (e.g., oral contraceptives, HRT): antagonizes therapeutic effect. - Cholestyramine or other bile‑acid sequestrants: decrease absorption of letrozole.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., fluvoxamine): may increase letrozole levels. - Anticoagulants (e.g., warfarin): potential alteration of INR, monitor coagulation. - SSRIs and SNRIs: may affect platelet function, observe bleeding risk. - Glucocorticoids: may increase risk of bone loss, monitor bone health.